314
Participants
Start Date
October 31, 2007
Primary Completion Date
March 31, 2009
Study Completion Date
March 31, 2009
placebo
Dosage: placebo, oral administration, Treatment duration: 13 weeks (1-week titration and 12-week fixed dose)
pregabalin
Dosage: 300 mg/day (150 mg bid), oral administration, Treatment duration: 13 weeks (1-week titration and 12-week fixed dose)
pregabalin
Dosage: 600 mg/day (300 mg bid), oral administration, Treatment duration: 13 weeks (1-week titration and 12-week fixed dose)
Pfizer Investigational Site, Nagoya
Pfizer Investigational Site, Chikushino-shi
Pfizer Investigational Site, Kasuga
Pfizer Investigational Site, Date-shi
Pfizer Investigational Site, Nihommatsu
Pfizer Investigational Site, Shirakawa-shi
Pfizer Investigational Site, Sukagawa
Pfizer Investigational Site, Kure
Pfizer Investigational Site, Chitose
Pfizer Investigational Site, Ebetu
Pfizer Investigational Site, Sapporo
Pfizer Investigational Site, Sapporo
Pfizer Investigational Site, Kobe
Pfizer Investigational Site, Inashiki
Pfizer Investigational Site, Kamakura
Pfizer Investigational Site, Yokohama
Pfizer Investigational Site, Yatsushiro
Pfizer Investigational Site, Sendai
Pfizer Investigational Site, Matsumoto
Pfizer Investigational Site, Ueda
Pfizer Investigational Site, Beppu
Pfizer Investigational Site, Yamada
Pfizer Investigational Site, Naha
Pfizer Investigational Site, Tomishiro
Pfizer Investigational Site, Urazoe
Pfizer Investigational Site, Higashiosaka
Pfizer Investigational Site, Hirano-ku
Pfizer Investigational Site, Kishiwada
Pfizer Investigational Site, Suminoe-ku
Pfizer Investigational Site, Sunto-gun
Pfizer Investigational Site, Oyama-shi
Pfizer Investigational Site, Utsunomiya
Pfizer Investigational Site, Arakawa City
Pfizer Investigational Site, Bunkyo-ku
Pfizer Investigational Site, Chiyoda-ku
Pfizer Investigational Site, Chuo-ku
Pfizer Investigational Site, Minato-ku
Pfizer Investigational Site, Nishitōkyō
Pfizer Investigational Site, Ohta-ku
Pfizer Investigational Site, Shibuya-ku
Pfizer Investigational Site, Fukuoka
Pfizer Investigational Site, Kumamoto
Pfizer Investigational Site, Nagasaki
Pfizer Investigational Site, Niigata
Pfizer Investigational Site, Okayama
Pfizer Investigational Site, Ōita
Pfizer Investigational Site, Saga
Pfizer Investigational Site, Saitama
Pfizer Investigational Site, Tokushima
Pfizer's Upjohn has merged with Mylan to form Viatris Inc.
INDUSTRY